Acquisition of high-level mupirocin resistance and its fitness cost among methicillin-resistant Staphylococcus aureus strains with low-level mupirocin resistance

Journal of Clinical Microbiology

Volumn 47, Issue 12, 2009, Pages 4158-4160

  Mongkolrattanothai, Kanokporn ^a   Pumfrey, Lisa ^a   Mankin, Peggy ^a   Gray, Barry M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; PSEUDOMONIC ACID;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PLASMID; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CONJUGATION, GENETIC; DRUG RESISTANCE, BACTERIAL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MUPIROCIN; PLASMIDS; STAPHYLOCOCCAL INFECTIONS;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

EID: 71549141294     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.01022-09     Document Type: Article

References (24)

1. Acton, D. S., M. J. Plat-Sinnige, W. van Wamel, N. de Groot, and A. van Belkum. 2009. Intestinal carriage of Staphylococcus aureus: how does its frequency compare with that of nasal carriage and what is its clinical impact? Eur. J. Clin. Microbiol. Infect. Dis. 28:115-127.
2. Antonio, M., N. McFerran, and M. J. Pallen. 2002. Mutations affecting the Rossman fold of isoleucyl-tRNA synthetase are correlated with low-level mupirocin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 46:438-442. (Pubitemid 34087193)
3. Bastos, M. C., P. J. Mondino, M. L. Azevedo, K. R. Santos, and M. Giambiagi-deMarval. 1999. Molecular characterization and transfer among Staphylococcus strains of a plasmid conferring high-level resistance to mupirocin. Eur. J. Clin. Microbiol. Infect. Dis. 18:393-398.
4. Berg, T., N. Firth, S. Apisiridej, A. Hettiaratchi, A. Leelaporn, and R. A. Skurray. 1998. Complete nucleotide sequence of pSK41: evolution of staphylococcal conjugative multiresistance plasmids. J. Bacteriol. 180:4350-4359. (Pubitemid 28405555)
5. Fujimura, S., and A. Watanabe. 2003. Survey of high- and low-level mupirocin-resistant strains of methicillin-resistant Staphylococcus aureus in 15 Japanese hospitals. Chemotherapy 49:36-38.
6. Hayakawa, T., T. Hayashidera, S. Katsura, K. Yoneda, and T. Kusunoki. 2000. Nasal mupirocin treatment of pharynx-colonized methicillin-resistant Staphylococcus aureus: preliminary study with 10 carrier infants. Pediatr. Int. 42:67-70.
7. Hodgson, J. E., S. P. Curnock, K. G. Dyke, R. Morris, D. R. Sylvester, and M. S. Gross. 1994. Molecular characterization of the gene encoding high-level mupirocin resistance in Staphylococcus aureus J2870. Antimicrob. Agents Chemother. 38:1205-1208.
8. Hughes, J., and G. Mellows. 1978. On the mode of action of pseudomonic acid: inhibition of protein synthesis in Staphylococcus aureus. J. Antibiot. (Tokyo) 31:330-335.
9. Hurdle, J. G., A. J. O'Neill, and I. Chopra. 2004. The isoleucyl-tRNA synthetase mutation V588F conferring mupirocin resistance in glycopeptide-intermediate Staphylococcus aureus is not associated with a significant fitness burden. J. Antimicrob. Chemother. 53:102-104.
10. Hurdle, J. G., A. J. O'Neill, E. Ingham, C. Fishwick, and I. Chopra. 2004. Analysis of mupirocin resistance and fitness in Staphylococcus aureus by molecular genetic and structural modeling techniques. Antimicrob. Agents Chemother. 48:4366-4376.
11. Jones, J. C., T. J. Rogers, P. Brookmeyer, W. M. Dunne, Jr., G. A. Storch, C. M. Coopersmith, V. J. Fraser, and D. K. Warren. 2007. Mupirocin resistance in patients colonized with methicillin-resistant Staphylococcus aureus in a surgical intensive care unit. Clin. Infect. Dis. 45:541-547.
12. Kresken, M., D. Hafner, F. J. Schmitz, and T. A. Wichelhaus. 2004. Prevalence of mupirocin resistance in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis: results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy, 2001. Int. J. Antimicrob. Agents 23:577-581.
13. McDougal, L. K., G. E. Fosheim, J. B. Patel, and A. Team. 2008. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. abstr. C1-166. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
14. Mongkolrattanothai, K., P. Mankin, V. Raju, and B. Gray. 2008. Surveillance for mupirocin resistance among methicillin-resistant Staphylococcus aureus clinical isolates. Infect. Control Hosp. Epidemiol. 29:993-994.
15. Pawa, A., W. C. Noble, and S. A. Howell. 2000. Co-transfer of plasmids in association with conjugative transfer of mupirocin or mupirocin and penicillin resistance in methicillin-resistant Staphylococcus aureus. J. Med. Microbiol. 49:1103-1107.
16. Ridenour, G., R. Lampen, J. Federspiel, S. Kritchevsky, E. Wong, and M. Climo. 2007. Selective use of intranasal mupirocin and chlorhexidine bathing and the incidence of methicillin-resistant Staphylococcus aureus colonization and infection among intensive care unit patients. Infect. Control Hosp. Epidemiol. 28:1155-1161.
17. Ringberg, H., A. C. Petersson, M. Walder, and P. J. H. Johansson. 2006. The throat: an important site for MRSA colonization. Scand. J. Infect. Dis. 38:888-893.
18. Sandri, A. M., M. G. Dalarosa, L. Ruschel de Alcantara, L. da Silva Elias, and A. P. Zavascki. 2006. Reduction in incidence of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection in an intensive care unit: role of treatment with mupirocin ointment and chlorhexidine baths for nasal carriers of MRSA. Infect. Control Hosp. Epidemiol. 27:185-187.
19. Schmitz, F. J., E. Lindenlauf, B. Hofmann, A. C. Fluit, J. Verhoef, H. P. Heinz, and M. E. Jones. 1998. The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. J. Antimicrob. Chemother. 42:489-495.
20. van Rijen, M. M., M. Bonten, R. P. Wenzel, and J. A. Kluytmans. 2008. Intranasal mupirocin for reduction of Staphylococcus aureus infections in surgical patients with nasal carriage: a systematic review. J. Antimicrob. Chemother. 61:254-261.
21. Vasquez, J. E., E. S. Walker, B. W. Franzus, B. K. Overbay, D. R. Reagan, and F. A. Sarubbi. 2000. The epidemiology of mupirocin resistance among methicillin-resistant Staphylococcus aureus at a Veterans' Affairs hospital. Infect. Control Hosp. Epidemiol. 21:459-464.
22. Watanabe, H., H. Masaki, N. Asoh, K. Watanabe, K. Oishi, S. Kobayashi, A. Sato, R. Sugita, and T. Nagatake. 2001. Low concentrations of mupirocin in the pharynx following intranasal application may contribute to mupirocin resistance in methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 39:3775-3777. (Pubitemid 32954545)
23. Wertheim, H. F., J. Verveer, H. A. Boelens, A. van Belkum, H. A. Verbrugh, and M. C. Vos. 2005. Effect of mupirocin treatment on nasal, pharyngeal, and perineal carriage of Staphylococcus aureus in healthy adults. Antimicrob. Agents Chemother. 49:1465-1467.
24. Zhang, K., J. Sparling, B. L. Chow, S. Elsayed, Z. Hussain, D. L. Church, D. B. Gregson, T. Louie, and J. M. Conly. 2004. New quadriplex PCR assay for detection of methicillin and mupirocin resistance and simultaneous discrimination of Staphylococcus aureus from coagulase-negative staphylococci. J. Clin. Microbiol. 42:4947-4955.